A neurobiological hypothesis for the classification of schizophrenia: Type a (hyperdopaminergic) and type b (normodopaminergic)

British Journal of Psychiatry

Volumn 205, Issue 1, 2014, Pages 1-3

  Howes, Oliver D ^a   Kapur, Shitij ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT;

DISEASE CLASSIFICATION; DOPAMINE METABOLISM; DRUG MECHANISM; HUMAN; HYPERDOPAMINERGIC SCHIZOPHRENIA; NEUROBIOLOGY; NORMODOPAMINERGIC SCHIZOPHRENIA; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE; BRAIN; CLASSIFICATION; DOPAMINERGIC NERVE CELL; METABOLISM;

BRAIN; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; SCHIZOPHRENIA;

EID: 84904004518     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.138578     Document Type: Review

References (12)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
2. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO,1992.
3. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69: 776-86.
4. Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 2011; 16: 885-6.
5. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012; 169: 1203-10.
6. Remington G, Kapur S, Foussias G, Agid O, Mann S, Borlido C, et al. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012; 32: 95-9.
7. Ottong SE, Garver DL. A biomodal distribution of plasma HVA/MHPG in the psychoses. Psychiatr Res 1997; 69: 97-103.
8. Yoshimura R, Ueda N, Shinkai K, Nakamura J. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 2003; 18: 107-11.
9. Roberts RC, Roche JK, Conley RR, Lahti AC. Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse 2009; 63: 520-30.
10. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104-9.
11. Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, et al. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res 2008; 106: 148-55.
12. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481-5.